Federal Contractor Profile
Locus Biosciences INC
Federal contracting record: $82M obligated across 2 awards from 1 agencies, FY 2020–2026.
$82M
Total Obligated
2
Award Records
1
Agencies Served
1
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
CJKVLKZGX6F3
CAGE Code
7H2T2
Address
523 DAVIS DR STE 350, MORRISVILLE, NC, 275607166
First Federal Award
Sep 28, 2020
Most Recent Award
Aug 26, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$82M
100.0% of total obligations
Top NAICS Activity
- $82M
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| May 11, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY | $4.6M |
| Sep 22, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY | $3.3M |
| Sep 16, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS | $18M |
| Feb 21, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS | $6.9M |
| Jan 19, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS | $24M |
| Feb 15, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS | $7.8M |
| Jun 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS | $6.2M |
| Sep 28, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS | $11M |
Want to win work like Locus Biosciences INC?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.